Skip to content

Systematic Review And Meta-Analysis Of Psoriasis Treatments.

Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01425138
Enrollment
1
Registered
2011-08-29
Start date
2009-06-30
Completion date
2011-06-30
Last updated
2018-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

psoriasis, systematic review, meta-analyses

Brief summary

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.

Detailed description

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.

Interventions

None listed

Sponsors

University of Connecticut School of Pharmacy and Hartford Hospital
CollaboratorUNKNOWN
Pfizer
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis. * Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion criteria

Observational studies * Trials that did not report the Physician's Global Assessment (PGA), * Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

Design outcomes

Primary

MeasureTime frame
Physician Global Assessment (PGA)
Dermatology Life Quality Index (DLQI)
Short-Form 36 (SF-36)

Secondary

MeasureTime frame
No secondary outcomesNo secondary outcomes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026